PMID: 9159161May 27, 1997Paper

Amphotropic murine leukemia viruses induce spongiform encephalomyelopathy

Proceedings of the National Academy of Sciences of the United States of America
C MünkC Stocking

Abstract

Recombinants of amphotropic murine leukemia virus (A-MuLV) have found widespread use in retroviral vector systems due to their ability to efficiently and stably infect cells of several different species, including human. Previous work has shown that replication-competent recombinants containing the amphotropic env gene, encoding the major SU envelope glycoprotein that determines host tropism, induce lymphomas in vivo. We show here that these viruses also induce a spongiform encephalomyelopathy in mice inoculated perinatally. This fatal central nervous system disease is characterized by noninflammatory spongiform lesions of nerve and glial cells and their processes, and is associated with moderate astro- and microgliosis. The first clinical symptoms are ataxia, tremor, and spasticity, progressing to complete tetraparesis and incontinence, and finally death of the animal. Sequences within the amphotropic env gene are necessary for disease induction. Coinfection of A-MuLV recombinants with nonneuropathogenic ecotropic or polytropic MuLV drastically increases the incidence, degree, and distribution of the neurodegenerative disorder. The consequence of these results in view of the use of A-MuLV recombinants in the clinic is discussed.

References

Jul 1, 1976·Journal of Virology·S RasheedE Chan
Oct 1, 1992·The Journal of Experimental Medicine·R E DonahueR Moen
Jan 1, 1990·Human Gene Therapy·A D Miller
Jan 1, 1990·Current Topics in Microbiology and Immunology·J L Portis
Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M GrezW Ostertag
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·Y PaquetteP Jolicoeur
Oct 1, 1973·Journal of the National Cancer Institute·M B GardnerR J Huebner
Dec 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·K HarbersR Jaenisch
Nov 1, 1995·Journal of Virology·D S RobbinsP M Hoffman
Jul 19, 1994·Proceedings of the National Academy of Sciences of the United States of America·M P KavanaughA D Miller
Jan 4, 1994·Proceedings of the National Academy of Sciences of the United States of America·D G MillerA D Miller
Feb 1, 1994·Proceedings of the National Academy of Sciences of the United States of America·M van ZeijlB O'Hara
Sep 10, 1996·Human Gene Therapy·G RossB R Smith

❮ Previous
Next ❯

Citations

Mar 10, 2001·Human Gene Therapy·B VogtD von Laer
Dec 23, 2006·European Journal of Oral Sciences·Dawei ZhaoAmel Gritli-Linde
Apr 25, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Christopher BaumMelanie Galla
Jun 17, 2005·Reviews in the Neurosciences·Esperanza Gomez-Lucia
Jan 4, 2003·Blood·Christopher BaumChristof von Kalle
Jun 23, 2016·Oncotarget·Andrey V ShubinSergey V Kostrov
Jun 11, 1999·Journal of Virology·H MileticD von Laer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.